Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Teri Buhl, who went to jail for harassment via the internet? That Teri Buhl?
Yes, maybe rising basis flawed technical analysis argument! You may be on to something!!!
Turning into a really nice day!
PumpTerminator got a margin call, forced to cover short at a huge loss? That the reason for this 10% pop on increasing volume?
Maybe writing libelous articles and publishing them on Seeking Alpha isn't the growth industry it once appeared?
best to all.
Thank you. THROWN OUT THREE TIMES is then an accurate statement regarding the Yidam law suit, just as I previously wrote. They're trying a fourth time hoping for a different result.
daBoze wrote:
The lawsuit filed by Yidam against Anil Diwan, whether an individual or a company, failed three times to gain acceptance in court. It has been filed again in a fourth jurisdiction and is likely to be thrown out again, Courts do defer to precedence in other jurisdictions.
best to all.
"The Plaintiff" can demand whatever he wants. But after losing this case already three times it doesn't seem likely he'll have any success demanding anything.
best to all.
My statement is accurate: THROWN OUT THREE TIMES!
Yidam keeps filing the suit, and losing, and then re-filing the same suit in another jurisdiction. He has lost three consecutive times in three jurisdictions, and perhaps is now trying a fourth in hopes of a different result.
Note that the "nanoviricides dot info" link resolves to a web site on which is posted the position of Yidam through his attorney. It is not an objective statement of fact.
And do you know... that one of Yidam's demands to NanoViricides was for a favorable stock arrangement which would have been illegal basis his relationship to the company? Did you know that? He was asking for an illegal transaction?
best to all
re: Biotech Firm Sued...
Somehow it was accidentally left out that the action described was THROWN OUT OF COURT THREE CONSECUTIVE TIMES in three different jurisdictions. Perhaps he's trying his luck in a fourth?
And further, the individual who brought that failed action -- Yidam -- has come out to state that the libelous Seeking Alpha article (in which the Yidam action was mentioned) misrepresents facts, writing:
Yidam does not condone the type of journalism that the article in question represents as it appears to be based upon conjecture and speculation. In addition, many references to the lawsuit mentioned in the article are inaccurate or taken out of context.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=98113055
Note that the "nanoviricides dot info" link resolves to a web site on which is posted the position of Yidam through his attorney. It is not an objective statement of fact.
best to all
Oh, forgot. Note that Teri Buhl (the source of the law suit story) spent time in jail and then probation for internet related harassment.
NNVC FluCide's EXCELLENT Pre-Clinical Results Recap!
Lest we forget in the swill of all the opposing points of view, here are snippets from yesterday's PR which detailed a recent presentation by company president Diwan to an Influenza Conference. His presentation recapped the EXCELLENT animal trial results which form the basis for the push toward human trials for FluCide. THIS is the science. In my opinion THIS is why this company will succeed and why share price will eventually explode.
http://finance.yahoo.com/news/nanoviricides-president-dr-diwan-presented-120000451.html
ALL of the FluCide treated animals survived, while NONE of the non-treated animals survived:
Dr. Diwan discussed the nanoviricides® technology platform, and presented the pre-clinical data on the Company’s first drug candidate, NV-INF-1, Injectable FluCide™, to treat all influenza infections in hospitalized patients. Influenza A H1N1 infected animals treated with FluCide survived the full 21-day observation period, whereas animals treated with 40mg/kg/d oseltamivir phosphate (Tamiflu®) survived only 8 days in this highly lethal study. Influenza A/WS/33/ (H1N1) virus was used in this study. The highly lethal infectious dose of 1M viral particles at time 0 h followed by another 1M virus particles at 23h that was employed caused uniform lethality in 5 days in untreated mice. Body weight began to decline in the infected, untreated mice, by days 2-3 days and continued to decline until death. The Oseltamivir-treated mice maintained body weight only through day 5, which declined thereafter until death. Similar to the survival results, the mice treated with NV-INF-1 maintained their body weight substantially longer, through day 14. NV-INF-1 demonstrated an unparalleled 1,000-fold reduction in lung viral load compared to untreated animals on day 4 in this lethal animal model study.
The pre-clinical safety profile for FluCide is extraordinary, essentially perfect:
Dr. Diwan also discussed the extremely high safety of NV-INF-1 observed in preliminary safety/toxicology studies. He noted that no significant changes in all observed parameters were found even at the maximum feasible dose of approximately 2,700 mg/kg/d repeatedly given for five consecutive days.
The potential market for the company's combined portfolio of drugs once through FDA approval in the coming years is HUGE:
The total market size addressed by the Company’s current drug programs is estimated at about $50 billion. In addition to Injectable FluCide, the Company is working on five more commercially important drug candidates, namely: DengueCide™, HerpeCide™, HIVCide™, Oral FluCide™ for out-patients, and a broad-spectrum antiviral drug for viral diseases of the external eye. All of our programs are for therapeutics to treat viral infections. Our drugs are expected to be useful as prophylactics as well. DengueCide has recently received orphan drug designation by the US FDA as well as the European EMA.
The company market cap is currently around $220M. If all drugs succeed through approval in the coming years (not guaranteed), picking a conservative multiplier of five times annual sales, on the high end the company could potentially be valued as high as $250B, for a one thousand times share price appreciation. In that best case scenario, share price under the current post-split structure could be north of $4,000 per share. Or under far more conservative assumptions, maybe share price appreciates only one forth that magnitude, to "only" $1,000 a share? Even reduce that by another factor of four... maybe "only" $250 a share?
Best to all.
The reason results in humans trials will likely be similar to those found in pre-clinicals in thousands of animals across multiple species rests in the manner of operation of NanoViricides' drugs.
Highly unusual relative to other types drugs, Viricides act totally independently of the animal's immune system. The Cides operate directly on the virus in the medium of the bloodstream. They attach to the virus particle in the bloodstream and physically rip it apart, harmlessly spilling it's contents. NanoViricides' drugs are specific to viral particles, while being agnostic as to host. There is therefore no anticipated scientific reason for human efficacy to be different from that demonstrated so overwhelmingly in pre-clinical animal studies.
Further, another potential for harm is avoided basis the fact that the Viricide drugs do not enter cells. They remain in the bloodstream. So, no interactions with species-specific structures.
So, we have our two factors. One, the drug's mechanism is likely to function perfectly as well in humans as it does in other animals because there's nothing specific to humans that's required for efficacy. And two, zero toxicity has been demonstrated in any animal tested in pre-clinicals, and there's no anticipated mechanism relative to humans which might cause an issue.
True, it will only be after the completion of human clinical trials that these statements are proven. However, appropriately so, share price currently reflects the pre-clinical status of the company's research. Huge share price appreciation will come as we get further down the road.
best to all.
Yes, which is part of the reason it's taken longer than expected for tox studies to begin. NanoViricides needs to produce far greater quantities of the drugs for the tox then they initially expected in order to attempt to demonstrate toxicity (something which has not been found in the thousands of animal administrations throughout pre-clinical testing).
I think they'll need to make enough to just drown the animals in it, because that might be the only way to show any harm.
best to all.
There was no "bitch slap", fanciful and imaginative as that sounds.
Again, from fiveeasypieces:
"There was no validation of the article in the court's opinion. In fact, quite the opposite as the court went out of it's way to distiguish between fact and opinion, the former being actionable and the latter being protected free speech. If anything was validated at all by the court it was that the Seeking Alpha article was opinion, not fact.
As for allegations that the case was, "thrown out," the only issue that was decided in the case was that the Company could not use pre-trial discovery to force Seeking Alpha to disclose the identity of the author. Hardly the, "pimp-slap," alleged in this post. Actually, maybe it was because I have no idea what is meant by, "pimp-slap," other than what it states on it's face, i.e. getting slapped by a pimp. Based on Judge Kern's order, this would hardly be an opinion, it would be an allegation of fact. But that's another case"
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=103936983
It's simply a link to Yidam's attorney's position.
Not a surprise that his lawyer's talking points might differ from reality. That is the job of an attorney, after all.
Best to all.
re: Biotech Firm Sued...
Somehow it was accidentally left out that the action described was THROWN OUT OF COURT THREE CONSECUTIVE TIMES in three different jurisdictions. Perhaps he's trying his luck in a fourth?
And further, the individual who brought that failed action -- Yidam -- has come out to state that the libelous Seeking Alpha article (in which the Yidam action was mentioned) misrepresents facts, writing:
Yidam does not condone the type of journalism that the article in question represents as it appears to be based upon conjecture and speculation. In addition, many references to the lawsuit mentioned in the article are inaccurate or taken out of context.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=98113055
Oh, and Teri Buhl (the source of the story) spent time in jail for internet related harassment.
best to all.
NNVC FluCide's EXCELLENT Pre-Clinical Results Recap!
Lest we forget in the swill of all the opposing points of view, here are snippets from today's PR recapping the EXCELLENT animal trial results for FluCide. THIS is the science. In my opinion THIS is why this company will succeed and why share price will eventually explode.
http://finance.yahoo.com/news/nanoviricides-president-dr-diwan-presented-120000451.html
ALL of the FluCide treated animals survived, while NONE of the non-treated animals survived:
Dr. Diwan discussed the nanoviricides® technology platform, and presented the pre-clinical data on the Company’s first drug candidate, NV-INF-1, Injectable FluCide™, to treat all influenza infections in hospitalized patients. Influenza A H1N1 infected animals treated with FluCide survived the full 21-day observation period, whereas animals treated with 40mg/kg/d oseltamivir phosphate (Tamiflu®) survived only 8 days in this highly lethal study. Influenza A/WS/33/ (H1N1) virus was used in this study. The highly lethal infectious dose of 1M viral particles at time 0 h followed by another 1M virus particles at 23h that was employed caused uniform lethality in 5 days in untreated mice. Body weight began to decline in the infected, untreated mice, by days 2-3 days and continued to decline until death. The Oseltamivir-treated mice maintained body weight only through day 5, which declined thereafter until death. Similar to the survival results, the mice treated with NV-INF-1 maintained their body weight substantially longer, through day 14. NV-INF-1 demonstrated an unparalleled 1,000-fold reduction in lung viral load compared to untreated animals on day 4 in this lethal animal model study.
The pre-clinical safety profile for FluCide is extraordinary, essentially perfect:
Dr. Diwan also discussed the extremely high safety of NV-INF-1 observed in preliminary safety/toxicology studies. He noted that no significant changes in all observed parameters were found even at the maximum feasible dose of approximately 2,700 mg/kg/d repeatedly given for five consecutive days.
The potential market for the company's combined portfolio of drugs once through FDA approval in the coming years is HUGE:
The total market size addressed by the Company’s current drug programs is estimated at about $50 billion. In addition to Injectable FluCide, the Company is working on five more commercially important drug candidates, namely: DengueCide™, HerpeCide™, HIVCide™, Oral FluCide™ for out-patients, and a broad-spectrum antiviral drug for viral diseases of the external eye. All of our programs are for therapeutics to treat viral infections. Our drugs are expected to be useful as prophylactics as well. DengueCide has recently received orphan drug designation by the US FDA as well as the European EMA.
The company market cap is currently around $220M. If all drugs succeed through approval in the coming years (not guaranteed), picking a conservative multiplier of five times sales, on the high end the company could potentially be valued at $250B, for a one thousand times share price appreciation. In that best case scenario, share price under the current post-split structure could be north of $4,000 per share. Or under far more conservative assumptions, maybe share price appreciates only one forth that magnitude, to "only" $1,000 a share.
Best to all.
Apologies to Teri Buhl. She's out of jail now, apparent:
http://www.newcanaannewsonline.com/news/article/Buhl-gets-30-days-jail-time-probation-and-4410428.php
No one has "their tail between their legs", fanciful as that sounds.
Again, from fiveeasypieces:
"There was no validation of the article in the court's opinion. In fact, quite the opposite as the court went out of it's way to distiguish between fact and opinion, the former being actionable and the latter being protected free speech. If anything was validated at all by the court it was that the Seeking Alpha article was opinion, not fact.
As for allegations that the case was, "thrown out," the only issue that was decided in the case was that the Company could not use pre-trial discovery to force Seeking Alpha to disclose the identity of the author. Hardly the, "pimp-slap," alleged in this post. Actually, maybe it was because I have no idea what is meant by, "pimp-slap," other than what it states on it's face, i.e. getting slapped by a pimp. Based on Judge Kern's order, this would hardly be an opinion, it would be an allegation of fact. But that's another case"
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=103936983
My statement is accurate: THROWN OUT THREE TIMES!
Yidam keeps filing the suit, and losing, and then re-filing the same suit in another jurisdiction. He has lost three consecutive times in three jurisdictions, and perhaps is now trying a fourth in hopes of a different result.
And do you know... that one of Yidam's demands to NanoViricides was for a favorable stock arrangement which would have been illegal basis his relationship to the company? Did you know that? He was asking for an illegal transaction?
best to all
"lots of selling"? "dumping"? Really???
Do the math. Of all those transactions, only the final ones from 2011, totaling only 55k shares, were sold above current market value, split adjusted. Fifty five thousand shares. That's about 20% of a single day's average volume sold at a small premium to current share price. The vast majority were sold below current share price.
"lots of selling"? Oooooooo... scary! Ooooo... something nefarious afoot! Oooooo... scam, fraud, blah, manipulation, blah, insider this and that, more blah more blah.
re: Biotech Firm Sued...
Somehow it was accidentally left out that the action described was THROWN OUT OF COURT THREE CONSECUTIVE TIMES.
And further, the individual who brought that failed action, Yidam, has come out to state that the libelous Seeking Alpha article (in which the Yidam action was mentioned) misrepresents facts, writing:
Yidam does not condone the type of journalism that the article in question represents as it appears to be based upon conjecture and speculation. In addition, many references to the lawsuit mentioned in the article are inaccurate or taken out of context.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=98113055
Oh, and Teri Buhl is currently in prison...
best to all.
Repeatedly saying something is one thing, when it is NOT that thing, does not make the repeated statement true.
There was no "bitch slap", fanciful as that sounds.
again:
"There was no validation of the article in the court's opinion. In fact, quite the opposite as the court went out of it's way to distiguish between fact and opinion, the former being actionable and the latter being protected free speech. If anything was validated at all by the court it was that the Seeking Alpha article was opinion, not fact.
As for allegations that the case was, "thrown out," the only issue that was decided in the case was that the Company could not use pre-trial discovery to force Seeking Alpha to disclose the identity of the author. Hardly the, "pimp-slap," alleged in this post. Actually, maybe it was because I have no idea what is meant by, "pimp-slap," other than what it states on it's face, i.e. getting slapped by a pimp. Based on Judge Kern's order, this would hardly be an opinion, it would be an allegation of fact. But that's another case"
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=103936983
The judge denied the NNVC petition to force SA to disclose the identity of the author. Nobody kicked the shit out of anyone. It was a simple pre-trial discovery motion. It wasn't a trial, it wasn't a case, it was a pre trial discovery motion. And that ruling does not preclude NNVC from future legal action. It was not a ruling on the merits or the veracity of the contents of the article.
As has been explained by fiveeasypieces:
"There was no validation of the article in the court's opinion. In fact, quite the opposite as the court went out of it's way to distiguish between fact and opinion, the former being actionable and the latter being protected free speech. If anything was validated at all by the court it was that the Seeking Alpha article was opinion, not fact.
As for allegations that the case was, "thrown out," the only issue that was decided in the case was that the Company could not use pre-trial discovery to force Seeking Alpha to disclose the identity of the author. Hardly the, "pimp-slap," alleged in this post. Actually, maybe it was because I have no idea what is meant by, "pimp-slap," other than what it states on it's face, i.e. getting slapped by a pimp. Based on Judge Kern's order, this would hardly be an opinion, it would be an allegation of fact. But that's another case"
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=103936983
Forget the Journal. What's Phil have to say about it???
It must be true. I read it in Phil's Stock World. Wow.....
"Phil's stock world". Seriously? Really?????
I'm waiting for the email from the Tooth Fairy claiming company officers Diwan and Seymour are from the planet Xenu, here to steal money from shareholders to build a space ship for their flight home.
"an email from a friend". nice.
And that's a hit piece from SEVEN YEARS AGO published on something as obscure as "Phil's Blog". So yes... we're now quoting seven year old hit pieces from a frickin' blog. Nice and timely and relevant.
It was utter nonsense seven years ago, and it's utter nonsense now.
Seriously.
Right. That would be the law suit that's been thrown out of court three consecutive times, and Teri Buhl would be the hack who's currently IN PRISON. Yes?
And by the way, the person who's brought that suit, Yidam, has REJECTED the Seeking Alpha libelous hit piece. Even THAT GUY knows the SA article was baseless and libelous.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=98113055
Any short thesis based upon denial of the actual proven science of this company is doomed to be a huge loser in the long run.
best to all.
This attack against the company is contrived, repugnant, and utterly baseless. The scenario described is wholly fictitious.
NNVC did NOT "lose a law suit". They simply failed to prevail on a motion to the NY court to force Seeking Alpha to disclose the identity of the anonymous author of the libelous article. It was a pre-trail discovery motion, not a "law suit".
Further, the judge did not rule on the veracity of the claims in the SA article, simply on the law regarding the request to force pre-trial disclosure of the name.
NanoViricides can still sue Seeking Alpha and/or John Doe for libel, and may yet do so.
Best to all.
Good plan! Be sure to ignore the science and trade basis what you read on message boards.
Best to all.
Here's the court's web site:
http://iapps.courts.state.ny.us/iscroll/CaseDetails.jsp?IndexNo=151908-2014
That's not true. The judge has not yet ruled.
It was originally "newsworthy" only in that it contained libelous, contrived, and non-factual statements which negatively and unjustifiably affected share price. Also newsworthy is the fact that the company has begun civil proceedings seeking relief from this act of libel by petitioning the NY civil Supreme Court to compel Seeking Alpha to disclose the name of the anonymous (for now) author of the libelous article.
The petition to compel SA to disclose the name was finally heard in court in early June and is in the hands of the judge. A ruling is expected any time, and the smart money says the judge will compel the release of the identity so that NanoViricides might serve process for a subsequent civil libel action against said author so that the question of libel can be adjudicated.
The author's right to print such statements is not yet at issue, as that will be the basis of the coming civil libel case. The current court proceeding simply seeks to compel Seeking Alpha to disclose the name of the author. There's no constitutional "1st amendment" right to anonymity. In this situation, the guarantee of anonymity for the author was a simple contract between the author and SA. It is clearly in the court's jurisdiction to order a disclosure of the name irrespective of that contract in the interest of justice.
Best to all.
SCARED SHORT ALERT
Persons short this company should definitely be very concerned that their short position is about to blow up in their faces. Too many things all coming together to support and extend share price.
Best to all.